prikaz prve stranice dokumenta What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
  Preuzmi
PDF 955.98 KB
Znanstveni rad - Izvorni znanstveni rad
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
Journal of Personalized Medicine, 11 (2021), 4; 269. https://doi.org/10.3390/jpm11040269
Basile, Vittoria; Puglisi, Soraya; Altieri, Barbara; Canu, Letizia; Libè, Rossella; Ceccato, Filippo; Beuschlein, Felix; Quinkler, Marcus; Calabrese, Anna; Perotti, Paola; Berchialla, Paola; Dischinger, Ulrich; Megerle, Felix; Baudin, Eric; Bourdeau, Isabelle; Lacroix, André; Loli, Paola; Berruti, Alfredo; Kaštelan, Darko; Haak, Harm R.; Fassnacht, Martin; Terzolo, Massimo Više autora...

Citirajte ovaj rad

Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F. ... Terzolo, M. (2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 11. (4). doi: 10.3390/jpm11040269

Basile, Vittoria, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of Personalized Medicine, vol. 11, br. 4, 2021. https://doi.org/10.3390/jpm11040269

Basile, Vittoria, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of Personalized Medicine 11, br. 4 (2021). https://doi.org/10.3390/jpm11040269

Basile, V., et al. (2021) 'What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question', Journal of Personalized Medicine, 11(4). doi: 10.3390/jpm11040269

Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, i sur.. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine [Internet]. 04.04.2021. [pristupljeno 09.10.2024.];11(4). doi: 10.3390/jpm11040269

V. Basile, et al., "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question", Journal of Personalized Medicine, vol. 11, br. 4, Travanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:323240. [Citirano: 09.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:323240
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
AutorVittoria Basile
AutorSoraya Puglisi
AutorBarbara Altieri
AutorLetizia Canu
AutorRossella Libè
AutorFilippo Ceccato
AutorFelix Beuschlein
AutorMarcus Quinkler
AutorAnna Calabrese
AutorPaola Perotti
AutorPaola Berchialla
AutorUlrich Dischinger
AutorFelix Megerle
AutorEric Baudin
AutorIsabelle Bourdeau
AutorAndré Lacroix
AutorPaola Loli
AutorAlfredo Berruti
AutorDarko Kaštelan
AutorHarm R. Haak
AutorMartin Fassnacht
AutorMassimo Terzolo
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Personalized Medicine
Brojčani podacivol. 11, br. 4, 269
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm11040269
URN:NBNurn:nbn:hr:105:323240
Datum objave publikacije2021-04-04
URL dokumentahttps://www.mdpi.com/2075-4426/11/4/269
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-01-11 09:48:52